Screener
Enovis ENOV Prevention & Recovery — Research and development expense
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Enovis in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Enovis’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 6:45 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001420800-26-000035
| Line item | Three Months Ended / July 3, 2026 | Three Months Ended / July 4, 2025 | Six Months Ended / July 3, 2026 | Six Months Ended / July 4, 2025 |
|---|---|---|---|---|
| Prevention & Recovery: | ||||
| Net sales | $288,248 | $290,570 | $560,266 | $563,154 |
| Segment cost of sales | 124,094 | 131,336 | 249,851 | 260,100 |
| Segment research and development | 7,706 | 9,669 | 15,453 | 18,910 |
| Segment operating expense | 111,250 | 107,523 | 223,720 | 215,367 |
| Total segment expenses | 243,050 | 248,528 | 489,024 | 494,377 |
| Add: Depreciation | 5,129 | 4,689 | 10,194 | 8,857 |
| Adjusted EBITDA (non-GAAP) | $50,327 | $46,731 | $81,436 | $77,634 |
Item 1. Financial Statements
FAQ
- What is Enovis's prevention & recovery — research and development expense?
- Enovis (ENOV) reported prevention & recovery — research and development expense of $7.71M in Q2 2026.
- What does prevention & recovery — research and development expense mean?
- The total expenditure dedicated to the discovery, design, and clinical testing of new medical technologies and product enhancements within the Prevention & Recovery segment. This investment is critical for maintaining the segment's competitive edge and driving long-term innovation in patient outcomes.
Ask your AI about Enovis's prevention & recovery — research and development expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude